Filing Flows › C4 Therapeutics (CCCC) › Q1 2025
C4 Therapeutics (CCCC) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
C4 Therapeutics (CCCC) reported revenue of $7.2M for the first quarter 2025 (Q1 2025), +138% from a year earlier and +40% from the quarter before. Operating margin was -402.9%, net loss $26.3M (363.7% of revenue).
C4 Therapeutics, Q1 2025: revenue $7.2M (+138% year over year), operating margin -402.9%, net loss $26.3M, operating cash flow −$33.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.2M | +40% | +138% |
| Operating profit | −$29.2M | — | — |
| Net earnings | −$26.3M | — | — |
| Operating cash flow | −$33.3M | — | — |
What changed
Revenue was $7.2M in Q1 2025, up 138% year over year and up 40% from the previous quarter.
Operating costs exceeded revenue by $29.2M, an operating margin of -402.9%. Total costs grew 3% against revenue growth of 138%. The fastest-growing cost line was Research & development (+20%). The quarter ended with a net loss of $26.3M, narrower than the previous quarter's $34.6M loss.
Operating cash flow was −$33.3M. Non-cash charges added back $456K of depreciation and amortization and $5.5M of share-based compensation. Working capital and other items used $12.9M.
Questions
What was C4 Therapeutics' revenue in the first quarter 2025?
C4 Therapeutics (CCCC) reported revenue of $7.2M for the first quarter 2025 (Q1 2025), +138% from a year earlier and +40% from the quarter before.
Was C4 Therapeutics profitable in the first quarter 2025?
Operating loss was $29.2M (-402.9% of revenue) and net loss $26.3M.
Source: C4 Therapeutics 10-Q on SEC EDGAR.